A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

NCT04494256 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

99

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: BIIB105
DRUG: Placebo

Sponsor

Biogen